ArticleLeukemia2017
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.Haematologica · 2026Article
- The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance.Frontiers in immunology · 2026Review
- Targeting the pDC/IFN-I axis in HIV-1 immunotherapy.Current opinion in HIV and AIDS · 2026Review
- Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.Blood advances · 2025Article
- Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.Hematology reports · 2023Review
- Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.Blood cancer journal · 2022Article
- Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.International journal of molecular sciences · 2022Review
- Myeloma Bone Disease: The Osteoblast in the Spotlight.Journal of clinical medicine · 2021Review
- Review
- Review
- Review
- Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma.Frontiers in oncology · 2021Review
- CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies.Cancers · 2020Review
- Multiple myeloma: the (r)evolution of current therapy and a glance into future.Haematologica · 2020Article
- Immunotherapeutic and Targeted Approaches in Multiple Myeloma.ImmunoTargets and therapy · 2020Review
- Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.OncoTargets and therapy · 2020Review
- The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Cellular immunology · 2019Review
- Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.Leukemia · 2019Article
- Review
- A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.The Journal of experimental medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host-MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance. Our studies showed increased numbers of tumor-promoting, immunosuppressive and drug-resistant plasmacytoid dendritic cells (pDCs) in the MM BM microenvironment. pDC-MM cell interactions upregulate interleukin-3 (IL-3), which stimulates both pDC survival and MM cell growth. Since IL-3 R is highly expressed on pDCs in the MM BM milieu, we here targeted pDCs using a novel IL-3 R-targeted therapeutic SL-401. In both in vitro and in vivo models of MM in its BM milieu, SL-401 decreases viability of pDCs, blocks pDC-induced MM cell growth, and synergistically enhances anti-MM activity of bortezomib and pomalidomide. Besides promoting pDC survival and MM cell growth, IL-3 also mediates progression of osteolytic bone disease in MM. Osteoclast (OCL) progenitor cells express IL-3 R, and we show that SL-401 abrogates monocyte-derived OCL formation and bone resorption. Finally, we show that SL-401 also decreases the viability of IL-3 R-expressing cancer stem-like cells in MM. Overall, our study provides the preclinical basis for clinical trials of SL-401 to block pDC-induced MM cell growth, inhibit osteoclastogenesis and target MM stem-like cell subpopulations to improve patient outcome in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.